Scinovex
article Open AccessTop 1% cited

Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection

Robert T. SchooleyBiswajit BiswasJason J. GillAdriana Hernandez-MoralesJacob LancasterLauren LessorJeremy J. BarrSharon L. ReedForest RohwerSean BenlerAnca M. SegallRandy TaplitzDavey M. SmithKim M. KerrMonika KumaraswamyVictor NizetLeo LinMelanie McCauleySteffanie A. StrathdeeConstance A. BensonRobert K. PopeBrian M. LerouxAndrew C. PicelAlfred MateczunKatherine E. CilwaJames RegeimbalLuis A. EstrellaDavid M. WolfeMatthew S. HenryJavier QuiñónesScott SalkaKimberly A. Bishop‐LillyRy YoungTheron Hamilton

Abstract

Widespread antibiotic use in clinical medicine and the livestock industry has contributed to the global spread of multidrug-resistant (MDR) bacterial pathogens, including <i>Acinetobacter baumannii</i> We report on a method used to produce a personalized bacteriophage-based therapeutic treatment for a 68-year-old diabetic patient with necrotizing pancreatitis complicated by an MDR <i>A. baumannii</i> infection. Despite multiple antibiotic courses and efforts at percutaneous drainage of a pancreatic pseudocyst, the patient deteriorated over a 4-month period. In the absence of effective antibiotics, two laboratories identified nine different bacteriophages with lytic activity for an <i>A. baumannii</i> isolate from the patient. Administration of these bacteriophages intravenously and percutaneously into the abscess cavities was associated with reversal of the patient's downward clinical trajectory, clearance of the <i>A. baumannii</i> infection, and a return to health. The outcome of this case suggests that the methods described here for the production of bacteriophage therapeutics could be applied to similar cases and that more concerted efforts to investigate the use of therapeutic bacteriophages for MDR bacterial infections are warranted.

Bacteriophages and microbial interactionsAntibiotic Resistance in BacteriaClostridium difficile and Clostridium perfringens researchAcinetobacter baumanniiLytic cycleAntibioticsMedicineBacteriophagePhage therapyIntensive care medicineAcinetobacterMicrobiologyAntibiotic resistance

MeSH terms

Phage TherapyAcinetobacter InfectionsAgedAnti-Bacterial AgentsBacteriophagesHumansMaleMinocyclinePancreatic PseudocystPancreatitis, Acute NecrotizingDrug Resistance, Multiple, BacterialAcinetobacter baumanniiGallstones

Funding

  • National Institute of Allergy and Infectious Diseases
Citations
1,213
FWCI
80.23
field-weighted impact
References
30
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.